. 2021 Sep 7;2021:5534873. doi: 10.1155/2021/5534873

Table 3.

Results obtained from comparison of cost-effectiveness of two treatment methods for atrial fibrillation patients.

	Strategy	Cost (PPP$)	Effectiveness (based on clinical outcomes)		Incremental cost	Incremental effectiveness		ICER (incremental cost per extra success) PPP$
	Strategy	Cost (PPP$)	Prevention of bleeding	Prevention of ischemic stroke	Incremental cost	Prevention of bleeding	Prevention of ischemic stroke	ICER (incremental cost per extra success) PPP$
Cost-effectiveness analysis (CEA)	Rivaroxaban	25275	0.82	0.99	0	0	0	Dominant
Cost-effectiveness analysis (CEA)	Warfarin	26554	0.44	0.96	1279	-0.38	-0.03	Dominated